Empowered Patient Podcast

Dr. Jim Woody, CEO and Director of 180 Life Sciences, discusses the company's vision for safer pain and inflammation management. Their earlier work on anti-TNF therapy revolutionized the treatment of conditions such as rheumatoid arthritis. Now 180 Life Sciences focuses on additional indications of inflammation, fibrosis, and cognitive dementia for using anti-TNFs. Jim highlights their research on the anti-inflammatory and analgesic properties of cannabinoids and the potential of synthetic cannabinoid analogs for pain management and appetite suppression. Jim elaborates, "Many years ago, I was Chief Scientific Officer at a company called Centocore, and they were one of the first companies developing therapeutic monoclonal antibodies. One of them that we developed was called anti-TNF. It was Infliximab, which was the FDA name that it received. In your body, circulating around, there are hundreds of small proteins. Those that modify the immune system are called cytokines, and most of them are good actors. One of